Comparative incidence of peripheral neuropathy associated with taxane chemotherapy in patients with breast cancer: A network meta-analysis
Bibliographic record
Abstract
IntroductionTaxane-induced peripheral neuropathy (TIPN) is a common toxicity among patients with breast cancer (BC). Numerous pairwise comparisons have been performed to evaluate neuropathy associated with different taxane agents (docetaxel, paclitaxel, cabazitaxel, nab-paclitaxel, liposomal paclitaxel, and paclitaxel injection concentrate for nanodispersion [PICN]). This network meta-analysis aimed to study the comparative incidence of TIPN associated with taxane agents in females with BC.MethodsA comprehensive data search was performed in PubMed, Web of Science, and Scopus up to August 2024. The studies that compare neuropathy in taxane agents were systematically reviewed. A network meta-analysis was carried out based on a Bayesian framework to evaluate the incidence of peripheral neuropathy in taxanes compared to paclitaxel, as reference comparator. The Surface Under the Cumulative Ranking Curve (SUCRA) was used to rank taxanes based on their neuropathy.ResultsA total of 27 studies with 12101 patients were included. When compared with paclitaxel, nab-paclitaxel was associated with a significantly higher incidence of peripheral neuropathy (OR: 1.74, CrI: 1.22-2.48). Docetaxel (OR: 0.626, CrI: 0.441-0.881) and cabazitaxel (OR: 0.158, CrI: 0.0664-0.375) demonstrated a significantly lower incidence of peripheral neuropathy compared to paclitaxel. Liposomal paclitaxel and PICN lack significant difference compared to paclitaxel. Our analysis provided the order for peripheral neuropathy (from lowest to highest) as follows: cabazitaxel, docetaxel, liposomal paclitaxel, paclitaxel, PICN, nab-paclitaxel.ConclusionsNab-paclitaxel is associated with a significantly higher incidence of peripheral neuropathy compared to paclitaxel in females with BC. Docetaxel and cabazitaxel are linked with less peripheral neuropathy compared with paclitaxel in this population. No significant differences were observed in liposomal paclitaxel and PICN compared to paclitaxel.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.018 | 0.030 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.009 | 0.048 |
| Bibliometrics | 0.006 | 0.006 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.003 | 0.001 |
| Open science | 0.002 | 0.002 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.004 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".